Novel apoE receptor mimetics reduce LPS-induced microglial inflammation

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Apolipoprotein E (apoE) and its mimetics possess anti-inflammatory properties.
• Novel apoE receptor mimetics were synthesized using the LDL receptor-binding domain of apoE.
• These mimetics include ApoEp, 6KApoEp (ApoEp with added lysines), and 6DApoEp (ApoEp with added aspartates).

Purpose of the Study:

• To determine the anti-inflammatory effects of novel apoE receptor mimetics.
• To investigate the mechanism of action, including interaction with LDL receptors and modulation of inflammatory signaling pathways.
• To evaluate the efficacy of 6KApoEp in a mouse model of neuroinflammation.

Main Methods:

• BV2 microglia and THP-1 monocytes were stimulated with lipopolysaccharide (LPS) and treated with apoE mimetics.
• Pro-inflammatory cytokines (TNFα, IL-6) were measured using ELISA.
• Western blot analysis was used to assess phosphorylation of STAT3, JAK2, and MAPK signaling pathways.
• Splenocytes from htau mice treated with 6KApoEp were analyzed for interferon gamma (IFNγ) release after concanavalinA stimulation.

Main Results:

• 6KApoEp significantly reduced LPS-induced TNFα and IL-6 secretion in a dose-dependent manner.
• 6KApoEp demonstrated greater efficacy in reducing TNFα secretion compared to 6DApoEp and ApoEp, an effect blocked by PCSK9, indicating LDL receptor involvement.
• 6KApoEp inhibited LPS-induced p44/42 MAPK, JAK2, and STAT3 phosphorylation while enhancing p38 MAPK phosphorylation.
• Treatment with 6KApoEp led to reduced IFNγ release in splenocytes from htau mice.

Conclusions:

• 6KApoEp is a potent anti-inflammatory agent that effectively reduces neuroinflammation.
• The mechanism involves interaction with LDL receptors and modulation of key inflammatory signaling pathways.
• 6KApoEp represents a promising novel therapeutic candidate for neurodegenerative diseases.